Biological drug and drug delivery-mediated immunotherapy.
Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W.
Acta Pharm Sin B. 2021 Apr;11(4):941-960. doi: 10.1016/j.apsb.2020.12.018. Epub 2020 Dec 31.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al.
Blood. 1995 Apr 15;85(8):2025-37.
Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
Ruan Y, Xie L, Zou A.
J Cancer Res Clin Oncol. 2023 Sep;149(12):10841-10850. doi: 10.1007/s00432-023-04974-x. Epub 2023 Jun 14.
MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW.
Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10.
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR.
Mol Biol Rep. 2021 Dec;48(12):8075-8095. doi: 10.1007/s11033-021-06752-9. Epub 2021 Oct 20.
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.
Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX.
Nat Biomed Eng. 2021 Nov;5(11):1261-1273. doi: 10.1038/s41551-021-00800-2. Epub 2021 Nov 1.
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity.
Koller P, Baran N, Harutyunyan K, Cavazos A, Mallampati S, Chin RL, Jiang Z, Sun X, Lee HH, Hsu JL, Williams P, Huang X, Curran MA, Hung MC, Konopleva M.
J Immunother Cancer. 2023 Oct;11(10):e006619. doi: 10.1136/jitc-2022-006619.
Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.
Yin J, Yin Q, Liang B, Mi R, Ai H, Chen L, Wei X.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):273-286. doi: 10.1007/s00210-019-01778-0. Epub 2019 Dec 14.
Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression.
Huang F, Li Z, Zhang W, Li J, Hao S.
Cancer Immunol Immunother. 2022 Sep;71(9):2197-2212. doi: 10.1007/s00262-021-03138-5. Epub 2022 Jan 29.
Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO, Sughayer M, Khader M, Tbakhi A, Khudirat S, Hejazi A, AlRyalat S, Bustami N, Aladily TN.
Clin Lab. 2022 Apr 1;68(4). doi: 10.7754/Clin.Lab.2021.210701.
